Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research

Abstract

Although gastrointestinal stromal tumors (GISTs) has been reported in patients of all ages, its diagnosis is more common in elders. The two most common types of mutation, receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor a (PDGFRA) mutations, hold about 75 and 15% of GISTs cases, respectively. Tumors without KIT or PDGFRA mutations are known as wild type (WT)-GISTs, which takes up for 15% of all cases. WT-GISTs have other genetic alterations, including mutations of the succinate dehydrogenase and serine-threonine protein kinase BRAF and neurofibromatosis type 1. Other GISTs without any of the above genetic mutations are named “quadruple WT” GISTs. More types of rare mutations are being reported. These mutations or gene fusions were initially thought to be mutually exclusive in primary GISTs, but recently it has been reported that some of these rare mutations coexist with KIT or PDGFRA mutations. The treatment and management differ according to molecular subtypes of GISTs. Especially for patients with late-stage tumors, developing a personalized chemotherapy regimen based on mutation status is of great help to improve patient survival and quality of life. At present, imatinib mesylate is an effective first-line drug for the treatment of unresectable or metastatic recurrent GISTs, but how to overcome drug resistance is still an important clinical problem. The effectiveness of other drugs is being further evaluated. The progress in the study of relevant mechanisms also provides the possibility to develop new targets or new drugs.

Keywords

GISTs / gene mutation / molecular mechanism / targeted therapies / drug resistance

Funding

This work was supported by the Tianjin Medical Key Discipline (Specialty) Construction Project (TJYXZDXK-058B) and the Tianjin Health Research Project (TJWJ2023XK014).

Conflict of Interest

None declared.

References

[1] Nannini M, Astolfi A, Urbini M, et al. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer 2014; 14: 685

[2] Arima J, Hiramatsu M, Taniguchi K, et al. Multiple gastrointestinal stromal tumors caused by a novel germline KIT gene mutation (Asp820Gly): a case report and literature review. Gastric Cancer 2020; 23[phone]

[3] Zhou S, Abdihamid O, Tan F, et al. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST. Cell Commun Signal 2024; 22(01) 153

[4] Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152[phone]

[5] Li J, Ye Y, Wang J, et al; Chinese Society Of Clinical Oncology Csco Expert Committee On Gastrointestinal Stromal Tumor. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res 2017; 29[phone]

[6] Napolitano A, Thway K, Smith MJ, Huang PH, Jones RL. KIT exon 9-mutated gastrointestinal stromal tumours: biology and treatment. Chemotherapy 2022; 67(02) 81-90

[7] Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours. Nat Rev Dis Primers 2021; 7(01) 22

[8] Casali PG, Abecassis N, Aro HT, et al; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv267

[9] Boikos SA, Pappo AS, Killian JK, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol 2016; 2[phone]

[10] Sawaki A. Rare gastrointestinal stromal tumors (GIST): omentum and retroperitoneum. Transl Gastroenterol Hepatol 2017; 2: 116

[11] Verschoor AJ, Bovée JVMG, Overbeek LIH, Hogendoorn PCW, Gelderblom H. PALGA group. The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study. Virchows Arch 2018; 472[phone]

[12] Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev 2015; 24[phone]

[13] Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am 2013; 42[phone]

[14] Nishida T, Goto O, Raut CP, Yahagi N. Diagnostic and treatment strategy for small gastrointestinal stromal tumors. Cancer 2016; 122(20) 3110-3118

[15] Schaefer IM, Mariño-Enríquez A, Fletcher JA. What is new in gastrointestinal stromal tumor?. Adv Anat Pathol 2017; 24[phone]

[16] Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 2016; 19(01) 3-14

[17] Lai S, Wang G, Cao X, et al. KIT over-expression by p55PIK-PI3K leads to imatinib-resistance in patients with gastrointestinal stromal tumors. Oncotarget 2016; 7[phone]

[18] Pantaleo MA, Nannini M, Corless CL, Heinrich MC. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med 2015; 4[phone]

[19] Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol 2016; 40: 39-46

[20] Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet 2013; 382(9896) 973-983

[21] Nannini M, Biasco G, Astolfi A, Pantaleo MA. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). J Med Genet 2013; 50(10) 653-661

[22] Machado I, Claramunt-Alonso R, Lavernia J, et al. ETV6:NTRK3 fusion-positive wild-type gastrointestinal stromal tumor (GIST) with abundant lymphoid infiltration (TILs and tertiary lymphoid structures): a report on a new case with therapeutic implications and a literature review. Int J Mol Sci 2024; 25(07) 3707

[23] Shi E, Chmielecki J, Tang CM, et al. FGFR1 and NTRK3 actionable alterations in “wild-type” gastrointestinal stromal tumors. J Transl Med 2016; 14(01) 339

[24] Wu J, Zhou H, Yi X, et al. Targeted deep sequencing reveals unrecognized KIT mutation coexistent with NF1 deficiency in GISTs. Cancer Manag Res 2021; 13: 297-306

[25] Gheorghe G, Bacalbasa N, Ceobanu G, et al. Gastrointestinal stromal tumors-a mini review. J Pers Med 2021; 11(08) 694

[26] Pathania S, Pentikäinen OT, Singh PK. A holistic view on c-Kit in cancer: structure, signaling, pathophysiology and its inhibitors. Biochim Biophys Acta Rev Cancer 2021; 1876[phone]

[27] Szucs Z, Thway K, Fisher C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol 2017; 13(01) 93-107

[28] Smrke A, Gennatas S, Huang P, Jones RL. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncol 2020; 16(22) 1639-1646

[29] Joensuu H, Rutkowski P, Nishida T, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol 2015; 33[phone]

[30] Calderillo-Ruíz G, Pérez-Yepez EA, García-Gámez MA, et al. Genomic profiling in GIST: implications in clinical outcome and future challenges. Neoplasia 2024; 48: 100959

[31] Brčić I, Argyropoulos A, Liegl-Atzwanger B. Update on molecular genetics of gastrointestinal stromal tumors. Diagnostics (Basel) 2021; 11(02) 194

[32] Wozniak A, Rutkowski P, Schöffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST. Clin Cancer Res 2014; 20(23) 6105-6116

[33] Casali PG, Abecassis N, Aro HT, et al; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv268-iv269

[34] Künstlinger H, Huss S, Merkelbach-Bruse S, et al. Gastrointestinal stromal tumors with KIT exon 9 mutations: update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Am J Surg Pathol 2013; 37(11) 1648-1659

[35] Zeng S, Seifert AM, Zhang JQ, et al. Wnt/β-catenin signaling contributes to tumor malignancy and is targetable in gastrointestinal stromal tumor. Mol Cancer Ther 2017; 16[phone]

[36] Niinuma T, Suzuki H, Sugai T. Molecular characterization and pathogenesis of gastrointestinal stromal tumor. Transl Gastroenterol Hepatol 2018; 3: 2

[37] Ito T, Yamamura M, Hirai T, et al. Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature. Int J Clin Exp Pathol 2014; 7(11) 8024-8031

[38] George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer 2009; 45: 1959-1968

[39] Corless CL, Schroeder A, Griffith D, et al. Heinrich M.C. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol 2005; 23: 5357-5364

[40] Masucci MT, Motti ML, Minopoli M, Di Carluccio G, Carriero MV. Emerging targeted therapeutic strategies to overcome imatinib resistance of gastrointestinal stromal tumors. Int J Mol Sci 2023; 24(07) 6026

[41] Pharaon N, Habbal W, Monem F. Bioinformatic analysis of KIT juxtamembrane domain mutations in Syrian GIST patients: jigsaw puzzle completed. J Egypt Natl Canc Inst 2023; 35(01) 25

[42] Shi X, Sousa LP, Mandel-Bausch EM, et al. Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition. Proc Natl Acad Sci U S A 2016; 113(33) E4784-E4793

[43] Reshetnyak AV, Opatowsky Y, Boggon TJ, et al. The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer. Mol Cell 2015; 57[phone]

[44] Obata Y, Horikawa K, Takahashi T, et al. Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors. Oncogene 2017; 36(26) 3661-3672

[45] Obata Y, Kurokawa K, Tojima T, et al. Golgi retention and oncogenic KIT signaling via PLCγ2-PKD2-PI4KIIIβ activation in gastrointestinal stromal tumor cells. Cell Rep 2023; 42[phone]

[46] Tsai M, Valent P, Galli SJ. KIT as a master regulator of the mast cell lineage. J Allergy Clin Immunol 2022; 149[phone]

[47] Masson K, Heiss E, Band H, Rönnstrand L. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. Biochem J 2006; 399(01) 59-67

[48] Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012; 92[phone]

[49] Zhao R, Song Y, Wang Y, et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. Cell Prolif 2019; 52(03) e12571

[50] Bosbach B, Rossi F, Yozgat Y, et al. Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. Proc Natl Acad Sci U S A 2017; 114(40) E8448-E8457

[51] Blay JY, Shen L, Kang YK, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 2015; 16[phone]

[52] Gastrointestinal Stromal Tumor Meta-Analysis G, Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28[phone]

[53] Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26[phone]

[54] Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26[phone]

[55] Cassier PA, Fumagalli E, Rutkowski P, et al; European Organisation for Research and Treatment of Cancer. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18(16) 4458-4464

[56] Debiec-Rychter M, Sciot R, Le Cesne A, et al; EORTC Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42[phone]

[57] Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24(29) 4764-4774

[58] Patrikidou A, Domont J, Chabaud S, et al; French Sarcoma Group. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer 2016; 52: 173-180

[59] Joensuu H, Wardelmann E, Eriksson M, et al. KIT and PDGFRA mutations and survival of gastrointestinal stromal tumor patients treated with adjuvant imatinib in a randomized trial. Clin Cancer Res 2023; 29(17) 3313-3319

[60] Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an exploratory analysis of a randomized clinical trial. JAMA Oncol 2017; 3[phone]

[61] Casali PG, Le Cesne A, Velasco AP, et al. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)*. Ann Oncol 2021; 32[phone]

[62] von Mehren M, Kane JM, Bui MM, et al. NCCN Guidelines insights: soft tissue sarcoma, version 1.2021. J Natl Compr Canc Netw 2020; 18(12) 1604-1612

[63] Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008; 216(01) 64-74

[64] Antonescu CR, DeMatteo RP. CCR 20th Anniversary Commentary: a genetic mechanism of imatinib resistance in gastrointestinal stromal tumor-where are we a decade later?. Clin Cancer Res 2015; 21(15) 3363-3365

[65] Hemming ML, Lawlor MA, Zeid R, et al. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A 2018; 115(25) E5746-E5755

[66] Reichardt P, Demetri GD, Gelderblom H, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer 2016; 16: 22

[67] Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer 2015; 121[phone]

[68] Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 2009; 15(22) 6862-6870

[69] Nishida T, Takahashi T, Nishitani A, et al; Japanese Study Group on GIST. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009; 14[phone]

[70] Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med 2017; 9 (414) eaao1690

[71] Gebreyohannes YK, Wozniak A, Zhai ME, et al. Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors. Clin Cancer Res 2019; 25[phone]

[72] Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020; 21[phone]

[73] Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 2019; 35 [phone].e9

[74] Janku F, Abdul Razak AR, Chi P, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib. J Clin Oncol 2020; 38(28) 3294-3303

[75] Basilio-de-Oliveira RP, Pannain VL. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World J Gastroenterol 2015; 21(22) 6924-6930

[76] Gromova P, Rubin BP, Thys A, Cullus P, Erneux C, Vanderwinden JM. ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours. J Cell Mol Med 2012; 16[phone]

[77] Ditsiou A, Cilibrasi C, Simigdala N, et al. The structure-function relationship of oncogenic LMTK3. Sci Adv 2020; 6 (46) eabc3099

[78] Klug LR, Bannon AE, Javidi-Sharifi N, et al. LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. Oncogene 2019; 38[phone]

[79] Stecca B, Ruiz i Altaba A. Context-dependent regulation of the GLI code in cancer by Hedgehog and non-Hedgehog signals. J Mol Cell Biol 2010; 2(02) 84-95

[80] Duan Y, Haybaeck J, Yang Z. Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: rationale and progress. Cancers (Basel) 2020; 12(10) 2972

[81] He W, Xu L, Ding J, et al. Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors. Biochim Biophys Acta Mol Basis Dis 2023; 1869[phone]

[82] Boichuk S, Galembikova A, Dunaev P, et al. A novel receptor tyrosine kinase switch promotes gastrointestinal stromal tumor drug resistance. Molecules 2017; 22(12) 2152

[83] Boichuk S, Galembikova A, Dunaev P, et al. Targeting of FGF-signaling re-sensitizes gastrointestinal stromal tumors (GIST) to imatinib in vitro and in vivo. Molecules 2018; 23(10) 2643

[84] Chaix A, Arcangeli ML, Lopez S, et al. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570. Oncogene 2014; 33[phone]

[85] Wong M, Funasaka K, Obayashi T, et al. AMPD3 is associated with the malignant characteristics of gastrointestinal stromal tumors. Oncol Lett 2017; 13[phone]

[86] Guérin A, Angebault C, Kinet S, et al. LIX1-mediated changes in mitochondrial metabolism control the fate of digestive mesenchyme-derived cells. Redox Biol 2022; 56: 102431

[87] Guérin A, Martire D, Trenquier E, et al. LIX1 regulates YAP activity and controls gastrointestinal cancer cell plasticity. J Cell Mol Med 2020; 24(16) 9244-9254

[88] Ruiz-Demoulin S, Trenquier E, Dekkar S, et al. LIX1 controls MAPK signaling reactivation and contributes to GIST-T1 cell resistance to imatinib. Int J Mol Sci 2023; 24(08) 7138

[89] Xu K, He Z, Chen M, et al. HIF-1α regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors. Cell Death Dis 2020; 11(07) 586

[90] Zhang T, Wang Y, Xie M, et al. HGF-mediated elevation of ETV1 facilitates hepatocellular carcinoma metastasis through upregulating PTK2 and c-MET. J Exp Clin Cancer Res 2022; 41(01) 275

[91] Cao L, Zheng K, Liu Y, et al. Identification of novel imatinib-resistant genes in gastrointestinal stromal tumors. Front Genet 2022; 13: 878145

[92] Boichuk S, Lee DJ, Mehalek KR, et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res 2014; 74[phone]

[93] Farag S, Somaiah N, Choi H, et al. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer 2017; 76: 76-83

[94] Kang HJ, Koh KH, Yang E, et al. Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations. Proteomics 2006; 6[phone]

[95] Wozniak A, Rutkowski P, Piskorz A, et al; Polish Clinical GIST Registry. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 2012; 23[phone]

[96] Indio V, Ravegnini G, Astolfi A, et al. Gene expression profiling of PDGFRA mutant GIST reveals immune signatures as a specific fingerprint of D842V exon 18 mutation. Front Immunol 2020; 11: 851

[97] Bannon AE, Klug LR, Corless CL, Heinrich MC. Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. Expert Rev Mol Diagn 2017; 17[phone]

[98] Wang C, Yantiss RK, Lieberman MD, et al. A rare PDGFRA exon 15 germline mutation identified in a patient with phenotypic manifestations concerning for GIST-plus syndrome: a case report and review of literature. Int J Surg Pathol 2023; 31[phone]

[99] von Mehren M, Joensuu H. Gastrointestinal stromal tumors. J Clin Oncol 2018; 36[phone]

[100] Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26(33) 5360-5367

[101] Farag S, Smith MJ, Fotiadis N, Constantinidou A, Jones RL. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates. Curr Treat Options Oncol 2020; 21(07) 55

[102] Grunewald S, Klug LR, Mühlenberg T, et al. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov 2021; 11[phone]

[103] Teuber A, Schulz T, Fletcher BS, et al. Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA. Nat Commun 2024; 15(01) 63

[104] Pitsava G, Settas N, Faucz FR, Stratakis CA. Carney triad, Carney-Stratakis syndrome, 3PAS and other tumors due to SDH deficiency. Front Endocrinol (Lausanne) 2021; 12: 680609

[105] Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology 2012; 44[phone]

[106] Schipani A, Nannini M, Astolfi A, Pantaleo MA. SDHA germline mutations in SDH-deficient GISTs: a current update. Genes (Basel) 2023; 14(03) 646

[107] Elston MS, Sehgal S, Dray M, et al. A duodenal SDH-deficient gastrointestinal stromal tumor in a patient with a germline SDHB mutation. J Clin Endocrinol Metab 2017; 102[phone]

[108] Moosavi B, Berry EA, Zhu XL, Yang WC, Yang GF. The assembly of succinate dehydrogenase: a key enzyme in bioenergetics. Cell Mol Life Sci 2019; 76(20) 4023-4042

[109] Kays JK, Sohn JD, Kim BJ, Goze K, Koniaris LG. Approach to wild-type gastrointestinal stromal tumors. Transl Gastroenterol Hepatol 2018; 3: 92

[110] Nannini M, Rizzo A, Indio V, Schipani A, Astolfi A, Pantaleo MA, Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol 2021; 13: 17 588359211023278

[111] Pantaleo MA, Lolli C, Nannini M, et al. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genet Med 2015; 17[phone]

[112] Gong QX, Ding Y, Zhang WM, Zhang JW, Zhang ZH. De novo dedifferentiated SDH-deficient gastrointestinal stromal tumor with MDM2 amplification: case report and literature review. Front Oncol 2023; 13: 1233561

[113] Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7(01) 77-85

[114] Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med 2011; 17(11) 641-649

[115] Raha S, McEachern GE, Myint AT, Robinson BH, Superoxides from mitochondrial complex III: the role of manganese superoxide dismutase. Free Radic Biol Med 2000; 29[phone]

[116] Xiao M, Yang H, Xu W, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012; 26(12) 1326-1338

[117] Wu CE, Tzen CY, Wang SY, Yeh CN. Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view. Cancers (Basel) 2019; 11(05) 679

[118] Indio V, Schipani A, Nannini M, et al. Gene expression landscape of SDH-deficient gastrointestinal stromal tumors. J Clin Med 2021; 10(05) 1057

[119] Giger OT, Ten Hoopen R, Shorthouse D, et al. Preferential MGMT hypermethylation in SDH-deficient wild-type GIST. J Clin Pathol 2023; 77(01) 34-39

[120] Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020; 21[phone]

[121] Weldon CB, Madenci AL, Boikos SA, et al. Surgical management of wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol 2017; 35[phone]

[122] Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21[phone]

[123] Casali PG, Blay JY, Abecassis N, et al; ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: [e-mail]. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2022; 33(01) 20-33

[124] Cohen NA, Zeng S, Seifert AM, et al. Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors. Cancer Res 2015; 75(10) 2061-2070

[125] Serrano C, Mariño-Enríquez A, Tao DL, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer 2019; 120[phone]

[126] Flavahan WA, Drier Y, Johnstone SE, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature 2019; 575(7781) 229-233

[127] von Mehren M, George S, Heinrich MC, et al. Linsitinib (OSI-906) for the treatment of adult and pediatric wild-type gastrointestinal stromal tumors, a SARC phase II study. Clin Cancer Res 2020; 26[phone]

[128] Glod J, Arnaldez FI, Wiener L, et al. A phase II trial of vandetanib in children and adults with succinate dehydrogenase-deficient gastrointestinal stromal tumor. Clin Cancer Res 2019; 25(21) 6302-6308

[129] Demetri GD, Reichardt P, Kang YK, et al; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381(9863) 295-302

[130] Ben-Ami E, Barysauskas CM, von Mehren M, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol 2016; 27[phone]

[131] Martin-Broto J, Valverde C, Hindi N, et al. REGISTRI: regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer 2023; 22(01) 127

[132] Lou L, Zhang W, Li J, Wang Y. Abnormal MGMT promoter methylation in gastrointestinal stromal tumors: genetic susceptibility and association with clinical outcome. Cancer Manag Res 2020; 12: 9941-9952

[133] Nannini M, Urbini M, Astolfi A, Biasco G, Pantaleo MA. The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST). J Transl Med 2017; 15(01) 113

[134] Pantaleo MA, Urbini M, Indio V, et al. Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST. Mol Cancer Res 2017; 15[phone]

[135] Mei L, Smith SC, Faber AC, et al. Gastrointestinal stromal tumors: the GIST of precision medicine. Trends Cancer 2018; 4(01) 74-91

[136] Huss S, Pasternack H, Ihle MA, et al. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. Hum Pathol 2017; 62: 206-214

[137] Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008; 47(10) 853-859

[138] Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol 2022; 19[phone]

[139] Jašek K, Váňová B, Grendár M, et al. BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): is their frequency underestimated?. Pathol Res Pract 2020; 216(11) 153171

[140] Torrence D, Xie Z, Zhang L, Chi P, Antonescu CR. Gastrointestinal stromal tumors with BRAF gene fusions. A report of two cases showing low or absent KIT expression resulting in diagnostic pitfalls. Genes Chromosomes Cancer 2021; 60(12) 789-795

[141] Gowda S, Sandow L, Heinrich MC. Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report. J Gastrointest Oncol 2024; 15[phone]

[142] Nishida T, Tsujimoto M, Takahashi T, Hirota S, Blay JY, Wataya-Kaneda M. Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. J Gastroenterol 2016; 51[phone]

[143] Agaimy A, Vassos N, Croner RS. Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol 2012; 5[phone]

[144] Arshad J, Ahmed J, Subhawong T, Trent JC. Progress in determining response to treatment in gastrointestinal stromal tumor. Expert Rev Anticancer Ther 2020; 20[phone]

[145] Segawa K, Sugita S, Sugawara T, et al. Multiple gastrointestinal stromal tumors involving extragastrointestinal sites in neurofibromatosis type 1. Pathol Int 2018; 68[phone]

[146] Burgoyne AM, De Siena M, Alkhuziem M, et al. Duodenal-jejunal flexure GI stromal tumor frequently heralds somatic NF1 and notch pathway mutations. JCO Precis Oncol 2017; 2017: PO.17.00014

[147] Mühlenberg T, Ketzer J, Heinrich MC, et al. KIT-dependent and KIT-independent genomic heterogeneity of resistance in gastrointestinal stromal tumors - TORC1/2 inhibition as salvage strategy. Mol Cancer Ther 2019; 18(11) 1985-1996

[148] Park EK, Kim HJ, Lee YH, Koh YS, Hur YH, Cho CK. Synchronous gastrointestinal stromal tumor and ampullary neuroendocrine tumor in association with neurofibromatosis type 1: a report of three cases. Korean J Gastroenterol 2019; 74[phone]

RIGHTS & PERMISSIONS

Global Medical Genetics